Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

4.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

291
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
291
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

219
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
219

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Tablet Computer-Based Food Record for the Self-Assessment of Nutritional Intake in Patients Undergoing Geriatric Rehabilitation: Prospective Pilot Feasibility Study.

JMIR aging·2026
Same author

Diversity- and culturally sensitive approaches in nutrition and fluid management in long-term nursing. A scoping review.

Journal of health, population, and nutrition·2026
Same author

Assessment of the ADLIFE intervention as a digital solution for patients with advanced chronic diseases: a quasi-experimental trial.

NPJ digital medicine·2026
Same author

Evaluation of the epidemiological and economic impact of the ADLIFE intervention on medium- to long-term in patients with advanced chronic disease.

Frontiers in public health·2025
Same author

Lossy DICOM conversion may affect AI performance.

Scientific reports·2025
Same author

User Experience and Usability Evaluation of the CAREPATH Adaptive Integrated Care Platform.

Studies in health technology and informatics·2025

Related Experiment Video

Updated: Apr 25, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

3.4K

Adverse drug event notification on a semantic interoperability framework.

Tobias Krahn1, Marco Eichelberg1, Frerk Müller1

  • 1OFFIS - Institute for Information Technology, Oldenburg, Germany.

Studies in Health Technology and Informatics
|August 28, 2014
PubMed
Summary

Adverse drug events (ADEs) are a significant issue in healthcare. The SALUS project developed a system using a Semantic Interoperability Layer (SIL) and ADE Detection and Notification Tool (ANT) to improve ADE detection from electronic health records.

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K
Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions
12:30

Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions

Published on: March 5, 2012

24.5K

Related Experiment Videos

Last Updated: Apr 25, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

3.4K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K
Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions
12:30

Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions

Published on: March 5, 2012

24.5K

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Health Informatics
  • Clinical Pharmacology

Background:

  • Adverse drug events (ADEs) pose a significant challenge in pharmacotherapy, leading to increased healthcare costs and patient harm.
  • Current pharmacovigilance relies heavily on spontaneous reporting systems, which are known for their ineffectiveness and underreporting.
  • Existing automated ADE detection systems often lack interoperability, being tied to proprietary interfaces of specific clinical information systems.

Purpose of the Study:

  • To develop a novel infrastructure and toolset for accessing and analyzing clinical patient data from heterogeneous electronic health record (EHR) systems.
  • To enhance the detection and reporting rates of ADEs by leveraging standardized methods for data access and analysis.
  • To address the limitations of current pharmacovigilance methods by creating an automated system for routine EHR data analysis.

Main Methods:

  • Development of a Semantic Interoperability Layer (SIL) to standardize data from disparate EHR sources into a common data model.
  • Integration of the SIL with an ADE Detection and Notification Tool (ANT) for automated analysis and identification of potential ADEs.
  • Utilizing standard methods for data access and interoperability within the SALUS project architecture.

Main Results:

  • The SALUS architecture, comprising the SIL and ANT, provides a unified approach to accessing and analyzing clinical data from various EHR systems.
  • The system facilitates the transformation of heterogeneous EHR data into a common data model, enabling more effective ADE detection.
  • The combined SIL and ANT components demonstrate the potential to significantly increase ADE detection and reporting rates in clinical practice.

Conclusions:

  • The SALUS project offers a robust solution for improving pharmacovigilance through automated ADE detection from routine EHR data.
  • The developed infrastructure and toolset can be implemented across diverse clinical environments to enhance patient safety.
  • This approach promises a substantial impact on the field of pharmacovigilance by improving the efficiency and effectiveness of drug safety surveillance.